TerminatedPhase 2NCT00285857

Phase 2 Study of Lovastatin as Breast Cancer Chemoprevention

Studying Hereditary breast cancer

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Stanford University
Principal Investigator
James Ford, MD
Stanford University
Intervention
Lovastatin(drug)
Enrollment
30 enrolled
Eligibility
18-65 years · FEMALE
Timeline
20052010

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00285857 on ClinicalTrials.gov

Other trials for Hereditary breast cancer

Additional recruiting or active studies for the same condition.

See all trials for Hereditary breast cancer

← Back to all trials